Plant Name: Fraxinus stylosa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.849E-10 | 3.661E-07 | CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, PTPN1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.684E-28 | 1.020E-23 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.633E-06 | 1.976E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| BP | GO:0050896; response to stimulus | GO:1901700; response to oxygen-containing compound | 3.786E-06 | 3.584E-03 | AKR1B1, CA3, CA9, CASP1, CYP1A2, HPGD, MAPK1, MMP2, MMP9, NFKB1, POLB, TSHR |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 6.462E-06 | 5.605E-03 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, CYP1A2, GAA, GFER, HPGD, HSD17B10, XDH |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.054E-05 | 7.651E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.129E-05 | 7.684E-03 | CA2, CA7 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.129E-05 | 7.684E-03 | ADRA2A, ADRA2C |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.535E-21 | 2.760E-17 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.841E-20 | 2.544E-16 | CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.889E-27 | 4.131E-25 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14; CA13 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.067E-06 | 7.626E-05 | MMP1; MMP2; MAPK1; MMP9 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.222E-05 | 5.826E-04 | CASP7; CASP1; MAPK1; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 9.499E-05 | 1.941E-03 | MMP1; MMP2; MAPK1; HIF1A; MMP9; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 5.536E-05 | 1.319E-03 | CASP7; MAPK1; MMP9; NFKB1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.480E-05 | 8.865E-04 | AKR1B10; GAA; AKR1B1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.411E-04 | 2.464E-03 | CASP7; LMNA; MAPK1; NFKB1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.551E-04 | 2.464E-03 | CASP7; CASP1; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 5.805E-04 | 6.922E-03 | MMP2; MAPK1; HIF1A; MMP9 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.725E-04 | 2.467E-03 | CASP1; MAPK1; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 9.275E-04 | 9.359E-03 | MMP2; MAPK1; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 8.752E-04 | 9.359E-03 | MMP2; MAPK1; MMP9 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 5.808E-04 | 6.922E-03 | CASP1; MAPK1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 9.817E-04 | 9.359E-03 | MAPK1; HIF1A; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.955E-03 | 1.472E-02 | AKR1B10; GAA; CYP1A2; ALOX15; ALDH1A1; AKR1B1; HSD17B10; XDH |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.835E-03 | 1.458E-02 | NMUR2; ADRA2C; ADRA2A; TSHR |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.666E-03 | 1.816E-02 | MAPK1; MMP9; NFKB1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 3.893E-03 | 2.461E-02 | MAPK1; ADRA2C; ADRA2A |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 4.437E-03 | 2.643E-02 | CASP1; MAPK1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.958E-03 | 2.461E-02 | CASP7; MAPK1; HSD17B10 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 4.799E-03 | 2.745E-02 | HPGD; MMP9; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 6.336E-03 | 2.854E-02 | MAPK1; NFKB1; TSHR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 6.876E-03 | 2.854E-02 | POLB; MAPK1; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 5.253E-03 | 2.854E-02 | MAPK1; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.503E-05 | 1.002E-03 | CYP1A2; XDH |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.382E-03 | 1.235E-02 | CYP1A2; ALOX15 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 5.805E-03 | 2.854E-02 | MAPK1; HIF1A |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 5.618E-03 | 2.854E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.126E-03 | 1.520E-02 | AKR1B10; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.682E-03 | 1.415E-02 | AKR1B10; AKR1B1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.984E-03 | 2.854E-02 | MAPK1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 6.984E-03 | 2.854E-02 | MAPK1; HIF1A |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 8.263E-03 | 3.034E-02 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 8.486E-03 | 3.034E-02 | MAPK1; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.781E-03 | 2.854E-02 | CYP1A2; ALDH1A1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 7.191E-03 | 2.856E-02 | MAPK1; HIF1A |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 6.580E-03 | 2.854E-02 | CASP1; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 8.486E-03 | 3.034E-02 | MAPK1; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 6.781E-03 | 2.854E-02 | MAPK1; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.241E-02 | 4.224E-02 | MAPK1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.294E-02 | 4.304E-02 | MMP2; MAPK1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 8.486E-03 | 3.034E-02 | MAPK1; NFKB1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 8.711E-03 | 3.038E-02 | PTPN1; MAPK1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; ACHE; ACHE; ACHE |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; MAPK1; CA9; MMP9; MMP2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; MAPK1; CA1; CA9; MMP9; NFKB1; MMP2; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1; ADRA2C; ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; ADRA2C |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2C; ADRA2A; ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; MMP1; AKR1B1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |